Tagged with Samsung BioLogics

Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…

South Korea As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top CDMO organizations, with revenues of USD 1.21 billion in 2021, is no exception. In response to increased demand, the firm…

Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…

South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…

Global The Contract Development and Manufacturing Organisation (CDMO) industry has boomed in recent years, with Big Pharma increasingly focusing on its core business of R&D and outsourcing other elements of the supply chain, including manufacturing, to third-party CDMOs. Additionally, the global proliferation of biotechs – most of which lack the in-house…

Korea After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge new manufacturing facilities to cope with increased demand, a dedication to carrying out technology transfers at half the speed of…

Korea Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s five largest COVID-19 vaccine manufacturing hubs by 2025. Here, we provide a rundown of some of the key companies involved…

China A roundup of the latest from Chinese pharma, including Green Valley’s upcoming US trial for an Alzheimer’s drug inspired by algae; Samsung Biologics expansion in China; Fosun Pharma’s halt to the development of a COVID-19 vaccine; and CAR-T biotech JW Therapeutics raising USD 300m in its IPO on the Hong…

Samsung Biologics It was less than a decade ago (2011) that Samsung Biologics was a new kid on the block amongst Korea’s booming biotech conglomerates. Since then the company has snowballed, building a series of progressively larger, more advanced facilities, culminating in its 180,000L “Dream Plant.” This facility, the largest single plant…

Top 10 Geoffrey Guy, David Meek, Tae Han Kim, Pierre Moustial, Vivek Sharma, Antonio Portela and many other remarkable people that are shaping the global life sciences industry shared with PharmaBoardroom valuable insights on the companies they lead and their vision for the future.   Geoffrey Guy Geoffrey Guy is the chairman and founder…

Korea In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment…